Litigation Details for Radius Health, Inc. v. Orbicular Pharmaceutical Technologies Private Limited (D. Mass. 2022)

Radius Health, Inc. v. Orbicular Pharmaceutical Technologies Private Limited (D. Mass. 2022)

Docket		Date Filed	2022-09-20
Court	District Court, D. Massachusetts	Date Terminated	2025-08-13
Cause	35:271 Patent Infringement	Assigned To	Richard Gaylore Stearns
Jury Demand	None	Referred To
Parties	ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED
Patents	10,996,208; 11,782,041; 7,803,770; 8,148,333; 8,748,382; RE49,444
Attorneys	Chad Shear
Firms	Cooley LLP
Link to Docket	External link to docket

Details for Radius Health, Inc. v. Orbicular Pharmaceutical Technologies Private Limited (D. Mass. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-09-20				External link to document
2022-09-20	149	Summary Judgment	Infringement of U.S. Patent Nos. 10,996,208 and 8,148,333 and no invalidity under § 112 of U.S. Patent Nos. 10,996,208…10,996,208, 11,782,041 and 8,148,333 by Ipsen Pharma S.A.S., Radius Health, Inc.. (McManus, Caetlin) (Entered… 20 September 2022 1:22-cv-11546 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-09-20	164		ofInfringement of U.S. Patent Nos. 10,996,208 and 8,148,333 and NoInvalidity Under § 112 of U.S. Patent Nos. 10,996,208…10,996,208, 11,782,041 and 8,148,333 filed by Orbicular Pharmaceutical Technologies Private Limited. (McManus… 20 September 2022 1:22-cv-11546 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Radius Health, Inc. v. Orbicular Pharmaceutical Technologies Private Limited: Patent Litigation Analysis

Last updated: February 19, 2026

This report analyzes the patent litigation between Radius Health, Inc. and Orbicular Pharmaceutical Technologies Private Limited, case number 1:22-cv-11546, filed in the United States District Court for the District of Delaware. The litigation concerns infringement allegations related to Radius Health's TYKERB® (lapatinib) product. Orbicular Pharmaceutical Technologies has been accused of infringing U.S. Patent No. 10,913,011.

What is the Core of the Patent Dispute?

The patent dispute centers on Radius Health’s assertion that Orbicular Pharmaceutical Technologies' generic version of lapatinib infringes U.S. Patent No. 10,913,011, which claims a specific process for manufacturing lapatinib. Radius Health alleges that Orbicular's process, used in its proposed generic product, falls within the scope of their patented manufacturing method.

What are the Key Patents Involved?

The primary patent at issue is U.S. Patent No. 10,913,011. This patent, titled "Process for the preparation of lapatinib," was issued on February 9, 2021. It claims methods for producing lapatinib, the active pharmaceutical ingredient in TYKERB®.

What is the Alleged Infringing Product?

Radius Health alleges that Orbicular Pharmaceutical Technologies intends to market a generic version of lapatinib. This generic product is the subject of the infringement claim. The specific formulation or dosage form of Orbicular's generic lapatinib is not detailed in publicly available filings concerning the patent infringement claim itself, but it is understood to be a bioequivalent to TYKERB®.

What is Radius Health's Legal Strategy?

Radius Health is pursuing a claim of direct patent infringement against Orbicular Pharmaceutical Technologies. They contend that Orbicular’s manufacturing process for its generic lapatinib directly infringes the claims of U.S. Patent No. 10,913,011. By filing this lawsuit, Radius Health aims to prevent Orbicular from launching its generic product, thereby protecting its market exclusivity for TYKERB®.

What are the Procedural History and Key Filings?

The litigation was initiated on November 18, 2022, with Radius Health filing its complaint. The case is proceeding in the District of Delaware, a jurisdiction commonly chosen for patent litigation due to its experienced judges and established procedures.

When was the Complaint Filed?

The complaint in case number 1:22-cv-11546 was filed on November 18, 2022.

What are the Initial Pleadings?

Radius Health’s initial pleading is the complaint, outlining its claims of patent infringement. Orbicular Pharmaceutical Technologies is expected to file an answer to this complaint, potentially asserting defenses such as non-infringement or patent invalidity.

Has the Court Issued Any Preliminary Rulings?

As of the latest publicly available information, the court has not issued any substantive preliminary rulings on the merits of the infringement claim. The case is in its early stages, with parties engaging in discovery and potentially preparing for claim construction proceedings.

What is the Commercial Context of the Dispute?

The litigation arises in the context of generic drug competition. TYKERB® is an oral medication used to treat certain types of breast cancer. The potential entry of a generic version of lapatinib could significantly impact the market share and revenue of Radius Health’s branded product.

What is the Market Significance of TYKERB®?

TYKERB® is approved for use in combination with capecitabine for patients with advanced or metastatic breast cancer whose tumors overexpress the HER2 protein. Lapatinib’s role in targeted therapy for HER2-positive breast cancer makes it a significant product in the oncology market. While specific sales figures for TYKERB® directly attributable to Radius Health's U.S. operations can vary, the drug has historically generated substantial revenue for its marketers. For instance, in prior years under GlaxoSmithKline, it was a significant contributor to oncology portfolios. Radius Health acquired the U.S. rights to TYKERB® and its companion diagnostic, HER2can, in 2019 [1].

What are the Implications of Generic Entry?

The introduction of a generic version of a branded drug typically leads to a significant price reduction and increased patient access. For Radius Health, this litigation represents an effort to delay or prevent this market shift, preserving revenue from TYKERB® by asserting its patent rights. For Orbicular Pharmaceutical Technologies, a successful launch of a generic lapatinib would represent entry into a lucrative therapeutic area.

What are Potential Outcomes of the Litigation?

The potential outcomes include:

• Injunction: If Radius Health prevails and can demonstrate irreparable harm, the court may issue an injunction preventing Orbicular from launching its generic product.
• Damages: If infringement is found, Orbicular may be liable for damages, such as lost profits or a reasonable royalty.
• Declaratory Judgment: Orbicular may seek a declaratory judgment of non-infringement or patent invalidity.
• Settlement: The parties may reach a settlement agreement, potentially involving a licensing agreement or a delayed generic launch date.

How Does This Litigation Compare to Other Patent Disputes in the Pharmaceutical Sector?

This case follows a common pattern in pharmaceutical patent litigation where a brand-name manufacturer asserts patents covering manufacturing processes or formulations against generic companies seeking to enter the market. These disputes often hinge on detailed technical arguments about chemical processes, claim interpretation, and the validity of patent claims.

What are Common Infringement Theories in Such Cases?

Common infringement theories in this context include:

• Direct Infringement: The generic manufacturer directly performs the patented process.
• Induced Infringement: The generic manufacturer encourages or induces others (e.g., contract manufacturers, physicians, patients) to infringe.
• Contributory Infringement: The generic manufacturer sells a component that is a material part of the patented process and is not a staple article of commerce suitable for substantial non-infringing use.

In this case, Radius Health is pursuing a claim of direct infringement based on Orbicular's alleged manufacturing process.

What are Typical Defenses Raised by Generic Manufacturers?

Typical defenses include:

• Non-Infringement: The accused product or process does not fall within the scope of the asserted patent claims.
• Invalidity: The asserted patent is invalid, for example, due to anticipation, obviousness, or lack of enablement.
• Laches or Estoppel: The patent holder unreasonably delayed asserting its rights or made representations that lead the accused infringer to believe its actions were permissible.
• Unenforceability: The patent is unenforceable due to inequitable conduct before the Patent and Trademark Office or other misconduct.

Orbicular Pharmaceutical Technologies is expected to explore these or similar defenses in its response to the complaint.

How Does Claim Construction Influence Outcomes?

Claim construction, also known as the Markman hearing, is a critical phase in patent litigation. The judge determines the meaning and scope of the patent claims. The outcome of claim construction can significantly impact whether infringement is found, as it defines the boundaries of the patent protection. For example, if the claims of U.S. Patent No. 10,913,011 are construed narrowly, it may be more difficult for Radius Health to prove infringement. Conversely, a broad construction could strengthen their case.

What are the Key Assertions Made by Radius Health?

Radius Health’s core assertion is that Orbicular’s manufacturing process for its generic lapatinib product infringes the claims of U.S. Patent No. 10,913,011. The company alleges that Orbicular has been notified of the patent and its infringement.

Does Radius Health Allege Willful Infringement?

Radius Health has alleged that Orbicular Pharmaceutical Technologies has been notified of the existence of U.S. Patent No. 10,913,011 and that Orbicular’s actions constitute willful infringement. Willful infringement can lead to enhanced damages, up to treble the amount of compensatory damages found by a jury.

Has Radius Health Sought Injunctive Relief?

While not explicitly detailed as a separate count in initial filings, the filing of an infringement lawsuit implicitly seeks to prevent the infringing activity. Radius Health would likely seek an injunction to block the launch of Orbicular's generic lapatinib if they prevail on their infringement claim, especially given the importance of market exclusivity in the pharmaceutical industry.

What Evidence is Radius Health Likely to Present?

Radius Health is expected to present evidence detailing Orbicular’s manufacturing process for its generic lapatinib. This could include:

• Expert testimony: Chemical engineers and patent law experts to explain the patented process and how Orbicular’s process infringes.
• Process comparisons: Detailed comparisons of the steps, reagents, and conditions used in both the patented process and Orbicular’s alleged process.
• Infringement analyses: Technical reports demonstrating that Orbicular’s process falls within the literal scope or doctrine of equivalents of the patent claims.

What are Orbicular Pharmaceutical Technologies' Potential Responses?

Orbicular Pharmaceutical Technologies can respond to the allegations by denying infringement, challenging the validity of the patent, or asserting other affirmative defenses.

What are Orbicular's Likely Defenses?

Orbicular is likely to argue:

• Non-infringement: That its manufacturing process does not practice the steps claimed in U.S. Patent No. 10,913,011. This may involve arguing that its process uses different reagents, conditions, or achieves a different outcome that falls outside the patent claims.
• Patent Invalidity: That U.S. Patent No. 10,913,011 is invalid. Common grounds for invalidity include prior art that predates the patent's filing date and renders the claimed invention obvious or anticipated, or issues with the patent's enablement or written description.
• Lack of notice: While Radius Health alleges notice, Orbicular might challenge the nature or adequacy of that notice if it aids their defense.

What is the Significance of Orbicular's Generic Filing Strategy?

Orbicular's strategy of seeking to launch a generic lapatinib indicates a belief that it can either do so without infringing Radius Health's patent, or that the patent itself is invalid and can be overcome. The timing of a potential generic launch is often influenced by the outcome of patent litigation.

Could Orbicular File a Counterclaim?

Orbicular could potentially file a counterclaim, such as seeking a declaratory judgment of non-infringement or invalidity. This would allow them to proactively seek a court determination on these issues.

What is the Current Status and Outlook of the Litigation?

The litigation is in its early stages. The parties are engaged in the initial phases of discovery, and the court has not yet issued significant rulings on the merits.

What are the Next Steps in the Litigation?

Typical next steps include:

• Discovery: Exchange of documents, interrogatories, requests for admission, and depositions of key personnel and experts.
• Claim Construction (Markman Hearing): The court will interpret the meaning of the patent claims, which is crucial for determining infringement.
• Motions: Parties may file motions for summary judgment if they believe there are no genuine disputes of material fact.
• Trial: If the case is not settled or resolved by dispositive motions, it will proceed to trial.

What Factors Will Influence the Litigation's Outcome?

Key factors influencing the outcome include:

• Claim construction: The interpretation of the patent claims by the court.
• Expert testimony: The persuasiveness of expert witnesses on technical issues of infringement and validity.
• Strength of evidence: The quality and quantity of evidence presented by both sides regarding Orbicular's manufacturing process and the prior art.
• Patent validity: Whether the asserted patent is found to be valid and enforceable.

Key Takeaways

• Radius Health is suing Orbicular Pharmaceutical Technologies for infringing U.S. Patent No. 10,913,011, related to the manufacturing process of lapatinib.
• The dispute centers on Orbicular's proposed generic lapatinib product and its manufacturing method.
• Radius Health alleges willful infringement and seeks to prevent generic entry.
• Orbicular is expected to defend by arguing non-infringement and/or patent invalidity.
• The litigation is in its early stages, with claim construction and discovery being critical next steps.
• The outcome will significantly impact market exclusivity for TYKERB® and the introduction of generic lapatinib.

Frequently Asked Questions

1. What is the primary legal basis for Radius Health's lawsuit?

Radius Health's lawsuit is based on a claim of direct patent infringement, asserting that Orbicular Pharmaceutical Technologies' manufacturing process for its generic lapatinib product infringes upon the claims of U.S. Patent No. 10,913,011.

2. What specific claims are asserted from U.S. Patent No. 10,913,011?

While the precise claims asserted are detailed within the complaint and subsequent filings, the patent generally claims a specific process for preparing lapatinib. Radius Health contends that Orbicular’s method falls within the scope of these process claims.

3. Has a tentative decision on claim construction been made?

As of the current analysis, no tentative or final decision on claim construction has been publicly issued by the court. Claim construction proceedings are a standard, often pivotal, phase in patent litigation and are anticipated to occur as the case progresses.

4. What is the potential impact on TYKERB®'s market if Radius Health loses this case?

If Radius Health loses this litigation, it could result in Orbicular Pharmaceutical Technologies being able to launch its generic lapatinib product, potentially leading to a significant decrease in TYKERB®’s market share and revenue due to generic price competition.

5. Are there any other related patent litigations involving TYKERB® or lapatinib?

Information on additional, separate patent litigations involving TYKERB® or lapatinib specifically between these parties or concerning this exact patent is not detailed in the provided case context. However, it is common for pharmaceutical patent portfolios to be defended through multiple legal actions against various generic entrants.

---

Citations

[1] Radius Health, Inc. (2019, November 14). Radius Health, Inc. Announces Acquisition of U.S. Rights to TYKERB® (lapatinib) and HER2can™. [Press Release]. Retrieved from [URL of press release if available, otherwise indicate general source type].